Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HydroGlyde Coatings has developed a patented condom coating that permanently bonds to latex and can be activated with water. This innovation aims to improve lubrication and reduce breakage compared to traditional silicone jelly-lubricated condoms. The company has secured three patents and IRB approval for human safety testing. They are in the process of securing FDA approval for clinical trials.[5]
"At HydroGlyde, they are developing a prototype latex design where the coating is permanently attached...and can be activated with a few drops of water...Currently...securing the necessary FDA approval for testing trials...3 patents granted..."[5]
No published clinical results yet; moving toward small human trial.
Commercialization will follow successful trial completion.
Pipeline breadth likely limited to one main program at this time.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HydroGlyde Coatings.